Patents Assigned to Gastrotech Pharma A/S
-
Publication number: 20090305964Abstract: The present invention relates to a kit of parts comprising a GLP-1 molecule and an anti-emetic drug, said kit of parts being suitable for separate, sequential or/and simultaneous administration to a subject, preferably a human being. Also provided are combinations of GLP-1 or a GLP-1 analog with one or more anti-emetic drugs, as well as uses of the combinations in the manufacture of medicaments.Type: ApplicationFiled: April 21, 2006Publication date: December 10, 2009Applicant: Gastrotech Pharma A/SInventors: Hans T. Schambye, Henrik Nilsson, Christian Hansen
-
Patent number: 7592305Abstract: The present invention relates to use of ghrelin or an analogue thereof for the preparation of a medicament for one or more of: treatment and/or prevention of loss of body weight and body fat, prophylaxis or treatment of cachexia, stimulation of appetite, stimulation of food intake, stimulation of weight gain, or increasing body fat mass, in a gastrectomized individual.Type: GrantFiled: October 9, 2003Date of Patent: September 22, 2009Assignee: Gastrotech Pharma A/SInventor: John-Olov Jansson
-
Publication number: 20090181887Abstract: The present invention relates to molecules, compositions and methods suitable for the treatment or prevention of biliary dyskinesia and/or pain and/or discomfort originating from the biliary tree. The peptide hormone glucagon-like peptide-1 (GLP-1) has both anti-secretory effects and smooth muscle relaxatory properties in the gastrointestinal tract. GLP-1 exists in several forms, where the natural occurring GLP-1 molecules are GLP-1 (1-37), GLP-1 (7-37), and the amidated versions GLP-1 (1-36)amide, GLP-1 (7-36)amide. Other molecules capable of binding to and activating the GLP-1 receptor is herein included in the tern GLP-1 molecules. GLP-1 molecules may be naturally occurring or homologues of GLP-1 having one or more amino acid substitutions or modifications. The GLP-1 molecules are used for the manufacture of a medicament for the treatment or prevention of biliary dyskinesia and/or pain and/or discomfort originating from the biliary tree.Type: ApplicationFiled: September 6, 2006Publication date: July 16, 2009Applicant: Gastrotech Pharma A/SInventors: Christian Hansen, Henrik Nilsson, Hans T. Schambye, Tina Geritz Nielsen
-
Publication number: 20080300180Abstract: The present invention relates to new growth hormone secretagogue receptor 1A (GHS-R 1A) ligands, and pharmaceutical compositions comprising any of the new GHS-R1 A ligands. The ligands are suitable for a wide range of applications, and thus the present invention also relates to use of the GHS-R1 A ligands according to the present invention in the manufacture of a medicament for the treatment of an individual in need thereof. In another aspect, the present invention relates to a method of treatment of an individual in need thereof, comprising administering to said individual one or more of the GHS-R1A ligands disclosed herein, such as e.g. for treatment of cancer cachexia.Type: ApplicationFiled: November 29, 2005Publication date: December 4, 2008Applicant: Gastrotech Pharma A/SInventors: Hans T. Schambye, Birgitte Holst Lange, Peter Holme Jensen
-
Publication number: 20080171700Abstract: The present invention relates to the use of a growth hormone (GH) secretagogue, such as a ghrelin-like compound, for the preparation of a medicament for the prophylaxis or treatment of ghrelin deficiency, and/or undesirable symptoms associated therewith, in an individual at risk of acquiring partial or complete ghrelin deficiency resulting from a medical treatment and/or from a pathological condition. The present invention also relates to use of a secretagogue compound for the preparation of a medicament for the prophylaxis or treatment of one or more of: loss of fat mass, loss of lean body mass, weight loss, cachexia, loss of appetite, immunological dysfunction, malnutrition, disrupted sleep pattern, sleepiness, reduction in intestinal absorption and/or intestinal mobility problems in an individual suffering from, or at risk of suffering from, ghrelin deficiency.Type: ApplicationFiled: April 7, 2005Publication date: July 17, 2008Applicant: Gastrotech Pharma A/SInventors: Henrik Nilsson, Birgitte Holst Lange, Claes Post, Tina Geritz Nielsen
-
Publication number: 20070037751Abstract: The present invention relates, in one aspect, to the use of a secretagogue compound for the preparation of a medicament for the prophylaxis or treatment of cancer cachexia in an individual in need of such treatment. In another aspect, the present invention relates to the use of a ghrelin-like compound for the preparation of a medicament for prophylaxis or treatment of cachexia in an individual by administering a subcutaneous dosage of said medicament to the individual. In a further aspect, the present invention relates to the use of a ghrelin-like compound or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulation of appetite in an individual by administering a subcutaneous dosage of said medicament to the individual. Furthermore, the present invention relates to a number of new ghrelin-like compounds and uses thereof, as well as to pharmaceutical compositions and medical packaging comprising the new ghrelin-like compounds.Type: ApplicationFiled: August 6, 2004Publication date: February 15, 2007Applicant: Gastrotech Pharma A/SInventors: Birgitte Lange, Christian Hansen, Henrik Nilsson
-
Publication number: 20060217296Abstract: The present invention relates to use of ghrelin or an analogue thereof for the preparation of a medicament for one or more of: treatment and/or prevention of loss of body weight and body fat, prophylaxis or treatment of cachexia, stimulation of appetite, stimulation of fool intake, stimulation of weight gain, or increasing body fat mass, in a gastrectomized individual.Type: ApplicationFiled: October 9, 2003Publication date: September 28, 2006Applicant: Gastrotech Pharma A/SInventor: John-Olov Jansson